First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome
This study is currently recruiting participants.
Verified January 2013 by Chiesi Farmaceutici S.p.A.
Sponsor:
Chiesi Farmaceutici S.p.A.
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier:
NCT01651637
First received: April 20, 2012
Last updated: January 30, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to investigate the safety and tolerability of intratracheal administration of two different single doses of CHF 5633 in preterm neonates with RDS in terms of adverse events, adverse drug reactions, hematology and biochemistry values, the incidence of major neonatal morbidities including bronchopulmonary dysplasia (BPD) and mortality.
| Condition | Intervention | Phase |
|---|---|---|
|
Respiratory Distress Syndrome in Premature Infants |
Drug: synthetic surfactant (CHF5633) |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A First in Human Clinical Study on the Safety and Tolerability of Two Escalating Single Doses of CHF 5633 (Synthetic Surfactant) in Preterm Neonates With Respiratory Distress Syndrome |
Resource links provided by NLM:
Further study details as provided by Chiesi Farmaceutici S.p.A.:
Primary Outcome Measures:
- Monitoring of adverse events following CHF5633 administration [ Time Frame: For duration of hospital stay (expected average of 9 weeks) ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- CHF 5633 efficacy profile (oxygenation , ventilatory requirements and need for rescue surfactant treatment),systemic absorption and immunogenicity assesment [ Time Frame: At min 30, at hrs 1, 3, 6, 12, 24, at days 2, 3, 7 and at days 10, 28, at 36 weeks pma post dosing for ventilatory requirements, at pre-dose and 3 hrs and 24 hrs post dosing for systemic absorption and at 8 wks after administration for immunogenicity ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | September 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Synthetic Surfactant
Cohort Design
|
Drug: synthetic surfactant (CHF5633)
CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
|
Detailed Description:
The study will be a multicentre, open-label, single escalating dose, per-cohort design.
Eligibility| Ages Eligible for Study: | 27 Weeks to 34 Weeks |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent obtained by parents/legal representative (according to local regulation) prior to any study-related procedures
- Inborn and outborn, preterm neonates of either sex with a gestational age of 27 weeks up to 33 weeks+6
- Clinical and radiological findings typical of RDS
- Age on admission to the study < 24 hours from birth
- Requirement of endotracheal intubation for surfactant administration
- Fraction of inspired oxygen (FiO2) > 0.35 to maintain SpO2 between 90-95 %
- Documentation of normal cranial ultrasound scan
Exclusion Criteria:
- Use of surfactant prior to study entry and need for intratracheal administration of any other treatment (e.g. nitric oxide)
- Known genetic or chromosomal disorders, major congenital anomalies (cardiac malformations, myelomeningocele etc)
- Maternal drug abuse (heroin, methadone, methamphetamine, or cocaine) or significant alcohol consumption during pregnancy
- Clinical chorioamnionitis (Appendix III)
- Strong suspicion of congenital pneumonia/infection, sepsis
- Evidence of severe birth asphyxia or a 5 minutes Apgar score less / equal 3
- Presence of air leaks prior to study entry
- Neonatal seizures prior to study entry
- Mothers with prolonged rupture of the membranes (> 3 weeks duration)
- Any condition that, in the opinion of the Investigator, would place the neonate at undue risk
- Participation in another clinical trial of any placebo, drug or biological substance conducted under the provisions of a protocol
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01651637
Contacts
| Contact: Guido Varoli | +390521279718 | g.varoli@chiesi.com |
Locations
| United Kingdom | |
| Liverpool Women's Hospital Neonatal Unit Liverpool Women's Hospital | Recruiting |
| Liverpool, United Kingdom | |
| Contact: Mark Turner, MD (0) 151-702-4101 ext +44 mark.turner@liverpool.ac.uk | |
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Investigators
| Principal Investigator: | Christian Speer, MD | Universitäts-Kinderklinik Würzburg (Germany) |
More Information
No publications provided
| Responsible Party: | Chiesi Farmaceutici S.p.A. |
| ClinicalTrials.gov Identifier: | NCT01651637 History of Changes |
| Other Study ID Numbers: | CCD-1011-PR-0059 |
| Study First Received: | April 20, 2012 |
| Last Updated: | January 30, 2013 |
| Health Authority: | Germany: Ethics Commission United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by Chiesi Farmaceutici S.p.A.:
|
Respiratory Distress syndrome Complications of prematurity |
Additional relevant MeSH terms:
|
Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Lung Diseases Respiratory Tract Diseases Respiration Disorders Infant, Premature, Diseases |
Infant, Newborn, Diseases Pulmonary Surfactants Respiratory System Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013